The Seoul Central District Court turned down SK Innovation's civil lawsuit and damage compensation filed against LG Chem in an electric vehicle (EV) battery patent case filed in October.
SK Innovation's lawsuit stemmed from a complaint filed by LG Chem against it at the International Trade Commissions (ITC) in April 2019 for poaching talents and trade secrets.
SK Innovation demanded that LG Chem dropped the complaint and compensate 1 billion won in damages based on their 2014 agreement that they would not engage in a legal battle concerning a specific technology, patented under the registration No. 775,310 in Korea.
Meanwhile, LG Chem pointed out that it can settle a dispute with SK Innovation over their EV battery trade secret case in the US if SK Innovation offers a "reasonable level" of compensation based on an objective basis.
LG Chem added that the legal process in Korea and at the ITC were separate, a point accepted by the court in Seoul.
SK Innovation will appeal the ruling with the Seoul High Court.
LG Chem vowed to pursue two legal actions against SK Innovation in the US unless the latter shows a sincere attitude.
The US International Trade Commission is scheduled to hand its final ruling in October.


Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push
Coty Revenue Beats Estimates as Beauty Demand Holds Firm
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows
Standard Chartered Expands Hedge Fund Access for Wealth Clients
Shein Targets $26B-$27B Valuation for Hong Kong IPO
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion
REPAY Stock Rises After Visa Platform Connect Collaboration
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate 



